Elin Trampe takes over as CEO of Dicot AB

Elin Trampe was hired by the company as COO and Deputy CEO in September 2021 and today succeeds Göran Beijer as CEO. Elin Trampe's main task as CEO will be to take the company into the next phase in the best way, where the focus will be on clinical studies, business development and partnerships with international pharmaceutical companies.

Dicot is developing the drug candidate LIB-01, which is expected to become a modern drug to better treat erectile dysfunction. The development is planned to take place in-house until phase 2 studies. Thereafter, Dicot's intention is to enter into collaboration agreements with established pharmaceutical companies to introduce LIB-01 on the world market.

"It's fantastic to lead a company that develops a new drug with potential to increase quality of life for so many people. This concerns more than half of all the world's men over 40 and their partners, and the need for new treatments is evident" says Elin Trampe, new CEO of Dicot.

Watch a filmed comment from Elin here.

"Elin has a very broad and valuable competence that is important to Dicot. With her strong drive and commitment, we will jointly with the rest of the management and the board, further develop the company as we now enter the next phase in the development of the company. ", says Eva Sjökvist Saers, Chairman of the Board of Dicot AB.

Elin Trampe has held several managerial and international roles in various companies and industries, including the global companies Mondelz International and GE Global Operations, as well as the pharmaceutical company Oasmia Pharmaceutical, where Elin had the role as CTO before joining Dicot. Elin Trampe has extensive experience in business development, strategic international partnerships, operational excellence and product development.

Göran Beijer will continue to be active in the company as a consultant with a focus on international partnerships and investor relations.